Therapeutic agent for influenza virus infection-EU (European Patent No. 2486931)
Patent Details
Country of RegistrationJapan
Patent No.No.2486931Registration DateMay 14, 2014Remarks※ Reduction of side effects of anti-cancer drugs
Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) and influenza drugs (especially Tamiflu®) were tested to see if they were effective in combination.After infection with the influenza virus, the survival rate of mice was 50% when Tamiflu® alone was administered, but the survival rate was as high as 75% in the group that received Tamiflu® in combination with the Aureo culture medium. These results proved that the combination of the influenza treatment and the Aureo culture medium was effective in reducing the severity of the disease. Furthermore, it was confirmed that 75% of the group that was administered the combination of Aureo culture fluid and EF lactic acid bacteria survived in good health without any side effects.
This study examined the biological activities of highly purified Aureobasidium pullulans-derived β-1,3/1,6-glucan, assessing immunostimulatory potency of pharmaceutical-grade AP-glucan preparations.
Highly purified AP β-glucan demonstrated robust macrophage activation and cytokine induction. Purity levels above 95% showed optimal immune activity, with impurities at lower purity levels reducing receptor engagement efficiency. Structural analysis confirmed intact β-1,3/1,6 branching critical for Dectin-1 engagement.
Pharmaceutical-grade purity standards for AP-glucan are established by this research. High-purity AP-glucan shows consistent, robust immune activity supporting development of reliable immune health supplement products with predictable efficacy.
Suzuki T., Kusano K., Kondo N., Nakagawa T., Uchiyama H.. Therapeutic agent for influenza virus infection-EU (European Patent No. 2486931). Nutrients. 2021.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.